Equity Profile

REGN

Regeneron Pharmaceuticals, Inc.

Health CareBiotechnology$64.5B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:30 AM EDT

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.00%

Metric	Actual	Expected	Surprise
EPS	$9.47	$8.84	+50.70%
Revenue	N/A	$3.5B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.00%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$9.47	$8.84	+50.70%
Revenue	N/A	$3.5B	N/A

Management Commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to long-term growth. However, they did not provide specific revenue figures or future guidance.

We are pleased with our EPS performance this quarter.

While we did not provide revenue figures, we remain focused on our long-term growth strategy.

What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the lack of revenue data and guidance may leave some uncertainty about future performance. The stock reaction remained flat, suggesting that investors are taking a wait-and-see approach following the earnings report.

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and manufactures medicines for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.

$8.84

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$3.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and manufactures medicines for serious diseases. Operating in the health care sector, it is known for its innovative treatments, particularly in eye diseases, cancer, and inflammatory conditions. With a market cap of $79 billion, Regeneron plays a significant role in advancing medical science and improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q4-2025, Regeneron reported an EPS of $11.44, significantly exceeding estimates by 38.18%. Despite this strong performance, the stock saw a slight decline of 1.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Regeneron to report strong earnings again, with a consensus EPS of $8.84. The company has a solid track record of beating earnings expectations, which could lead to positive market reactions.

Bull Case

If Regeneron continues its trend of exceeding earnings estimates, it could see a significant stock price increase, especially if revenue also comes in strong.

Bear Case

Conversely, if the company fails to meet earnings expectations or if revenue growth slows, it could lead to a negative reaction in the stock price.

Key Metrics to Watch

EPS

$8.84

Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.

Revenue

$3.5B

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $8.84?

Given Regeneron's history of beating EPS estimates, this will be a critical factor in determining market reaction.

What is the revenue forecast for this quarter, especially in light of recent product launches?

Revenue growth is essential for sustaining investor confidence and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Regeneron's ability to leverage its recent product launches for revenue growth, especially in the oncology segment.

Supporting Evidence

Regeneron has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent insider buying activity could signal confidence in upcoming results.

Key Risk

If revenue growth exceeds $3.8B, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can maintain its strong earnings momentum amid competitive pressures and market conditions.

Bull Confirmed If

An EPS of $10.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $7.00 would confirm the bear case, suggesting potential issues in sales or cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±7.28%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant potential price movement, indicating that traders expect volatility around the earnings report.

Options are pricing ±7.1% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

22.6%

Calls (86K)P/C Ratio: 1.38Puts (161K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests the stock could rise by about 0.85% on the following day, confirming continued strength.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline in stock price, with historical patterns suggesting an average drop of around 6.87%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive pressures in the biotechnology sector.
3Insights into cost management strategies and their effect on margins.
4Discussion of regulatory developments that could affect product approvals.
5Any guidance on future earnings expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and manufactures medicines for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.

$8.84

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$3.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q4-2025, Regeneron reported an EPS of $11.44, significantly exceeding estimates by 38.18%. Despite this strong performance, the stock saw a slight decline of 1.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Regeneron continues its trend of exceeding earnings estimates, it could see a significant stock price increase, especially if revenue also comes in strong.

Bear Case

Conversely, if the company fails to meet earnings expectations or if revenue growth slows, it could lead to a negative reaction in the stock price.

Key Metrics to Watch

EPS

$8.84

Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.

Revenue

$3.5B

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $8.84?

Given Regeneron's history of beating EPS estimates, this will be a critical factor in determining market reaction.

What is the revenue forecast for this quarter, especially in light of recent product launches?

Revenue growth is essential for sustaining investor confidence and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Regeneron's ability to leverage its recent product launches for revenue growth, especially in the oncology segment.

Supporting Evidence

Regeneron has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent insider buying activity could signal confidence in upcoming results.

Key Risk

If revenue growth exceeds $3.8B, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can maintain its strong earnings momentum amid competitive pressures and market conditions.

Bull Confirmed If

An EPS of $10.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $7.00 would confirm the bear case, suggesting potential issues in sales or cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±7.28%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant potential price movement, indicating that traders expect volatility around the earnings report.

Options are pricing ±7.1% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

22.6%

Calls (86K)P/C Ratio: 1.38Puts (161K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests the stock could rise by about 0.85% on the following day, confirming continued strength.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline in stock price, with historical patterns suggesting an average drop of around 6.87%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive pressures in the biotechnology sector.
3Insights into cost management strategies and their effect on margins.
4Discussion of regulatory developments that could affect product approvals.
5Any guidance on future earnings expectations and market conditions.